TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Dehydroepiandrosterone (DHEA) and Letrozole in Treating Patients With Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of breast cancer~  * Metastatic disease~* Hormone receptor status~  * Estrogen receptor- and progesterone receptor-negative~ * Androgen receptor-positive~PATIENT CHARACTERISTICS:~* ECOG performance status 0-3~* Postmenopausal (\> 60 years of age)~* Leukocyte count \> 3,000/uL~* Absolute neutrophil count \> 1,500/uL~* Platelet count \> 100,000/uL~* Total bilirubin normal~* AST and ALT \< 2.5 times upper limit of normal~* Creatinine normal OR creatinine clearance \> 60 mL/min~PRIOR CONCURRENT THERAPY:~* At least 4 weeks since prior chemotherapy~* At least 4 weeks since prior biologic therapy~* At least 4 weeks since prior radiotherapy~* At least 30 days since prior investigational agents~* No concurrent dehydroepiandrosterone or androstenedione supplements~* No concurrent chemotherapy or radiotherapy~* No concurrent hormone therapy or immunotherapy (including trastuzumab \[Herceptin®\])

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Traxi Panniculus Retractor for Cesarean Delivery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pregnant~* BMI greater than or equal to 40 kg/m\^2~* Undergoing non-emergent cesarean delivery~* Able and willing to provide written, informed consent~* Singleton gestation~Exclusion Criteria:~* Fetal demise~* Disruption of abdominal skin (infection, rash, abrasion, laceration)~* Known adhesive allergy

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Traxi panniculus retraction group (Type: EXPERIMENTAL): The method of panniculus retraction will be the Traxi panniculus retraction (Clinical Innovations, LLC) by the provider.
- Standard of care (Type: NO_INTERVENTION): Standard methods of panniculus retraction as determined by individual provider (including medical taping, extra personnel for retraction)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Total Marrow Irradiation With High Dose Melphalan Prior to Autologous Transplant for Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients meeting criteria for symptomatic myeloma~2. Patients must be high or intermediate risk of disease progression as defined by having one of the following criteria: 2.1 ISS stage 2 or 3 disease 2.2 Abnormal metaphase cytogenetics 2.3 Presence of FISH abnormalities aside from hyperdiploidy~3. Patients who have received at least 2 cycles of systemic treatment of any kind in the preceding 12 months~4. Patient age 18-75 years at time of enrollment~5. Karnofsky performance status of ≥70~6. Cardiac function: LVEF \>40%~7. Hepatic: Bilirubin \<2x upper limit of normal and ALT and AST \< 2.5x the upper limit of normal~8. Renal: Creatinine clearance of ≥30mL/min, estimated or calculated~9. Pulmonary: DLCO, FEV1, FVC \>50% of predicted (after correction for hemoglobin)~Exclusion Criteria:~1. Patients with diagnosis of plasma cell leukemia~2. Patients with myeloma who have had any disease progression prior to enrollment~3. Patients with truly non secretory myeloma (patients with light chain disease are eligible)~4. Pregnant or breast-feeding~5. Uncontrolled viral, fungal or bacterial infection Note: Infection is permitted if there is evidence of response to medication. Eligibility of HIV infected patients will be determined on a case-by-case basis.~6. Patients who have undergone prior allograft or autologous transplant~7. Prior solid organ transplant~8. Patients receiving prior radiation to more than 20% of bone marrow containing areas

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Total Marrow Irradiation (Type: EXPERIMENTAL): Escalating doses of total marrow irradiation (3Gy, 6Gy, 9Gy, or 12Gy) with standard high dose melphalan prior to autologous stem cell rescue.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Anemia in Diabetic Subjects With CKD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects with a clinical diagnosis of diabetes mellitus~* History of documented proteinuria or microalbuminuria~* A glomerular filtration rate between 15 and 90 mL/minute/1.73m2~* Subjects with hemoglobin greater than or equal to 9.0 /dL and less than or equal to 11.0 g/dL.~Exclusion Criteria:~* A current diagnosis of poorly controlled high blood pressure (hypertension) (systolic blood pressure \> 150 mm Hg or diastolic blood pressure \> 100 mm Hg) after adequate anti hypertensive therapy~* Subjects with severe neuropathy or peripheral vascular disease with gait instability~* Subjects scheduled to receive dialysis during the course of the study~* Subjects with a transferrin saturation \< 20% or ferritin level \< 50 ng/dL~* Subjects with active malignancy, defined as a malignancy requiring current therapy (surgery, chemotherapy, or radiotherapy) or a history of treatment for malignancy in the last 5 years.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Prophylactic Octreotide to Prevent Post Duodenal EMR and Ampullectomy Bleeding

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Duodenal or ampullary adenoma greater than or equal to 10mm Duodenal or ampullary adenoma that is suitable for endoscopic mucosal resection Medically fit for anesthesia, endoscopy, and EMR Able to provide Informed Consent 18 years or older, male and female~Exclusion Criteria:~Duodenal or ampullary adenoma \<10mm Duodenal or ampullary adenoma that is not suitable for endoscopic mucosal resection Medically unfit for anesthesia, endoscopy, or EMR Unable to provide informed consent Less than 18 years old Allergy to Octreotide

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 89 Years
- Healthy Volunteers: f

Study Arms:
- Octreotide (Type: EXPERIMENTAL): Octreotide 100mcg subcutaneous every 8 hours for 5 days
- no octreotide (Type: OTHER): No Octreotide

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Epidemiology of Sleep Apnea Syndrome

Study Design Characteristics:
- Allocation: N/A
- Intervention Model: N/A
- Observational Model: N/A
- Primary Purpose: N/A
- Time Perspective: N/A
- Masking: N/A
- Phase: None
- Number of Arms: None

Eligibility Criteria:
No eligibility criteria

- Gender: MALE
- Minimum Age: 0 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Local Anesthesia in Patients With Marginal Periodontitis Undergoing Scaling and Root Planning

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients diagnosed as having, respectively periodontitis marginalis adulta progressiva lenta and periodontitis marginalis adulta progressiva rapid in the hygiene phase, where depurations are repeated within a short timeframe~* Age between 18 and 80 years~* Ability to speak, read and understand danish~* Ability to give oral and written consent~Exclusion Criteria:~* Known allergy to bupivacaine or other local anaesthetics of the amide type~* Other gingival infections (eg lichen planus)~* Pregnancy -if in doubt a pregnancy test will be made~* Breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Bupivacaine lozenge (Type: EXPERIMENTAL): Single dose administration of a 25 mg bupivacaine lozenge before the scaling and root planning was performed.
- Lidocaine-adrenalin injection (Type: ACTIVE_COMPARATOR): Xyloplyin Dental Adrenalin (20 mg/ml lidocaine, 12.5 microgram/ml adrenaline). Frequency and duration of injections was decided by the dentist preforming the scaling and root planning.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent~* Unresectable or metastatic pancreatic cancer~* Persistent cancer after at least one prior standard of care chemotherapy for advanced stage disease~* 18 years of age and older~* ECOG performance status of 0 or 1~* Life expectancy greater than 3 months~* Satisfactory organ and bone marrow function~* Meets blood coagulation parameters~* Male and Female subjects of reproductive potential agree to use approved contraceptive methods~Exclusion Criteria:~* Participation in a therapeutic investigational study within 4 weeks prior to the screening visit~* Anticipated need for systemic chemotherapy within 2 weeks before apheresis and infusion~* Active invasive cancer other than pancreatic cancer~* HIV, HCV, or HBV infections~* Active autoimmune disease requiring immunosuppressive therapy within 4 weeks prior to screening visit, with exception of thyroid replacement~* Ongoing or active infection~* Planned concurrent treatment with systemic high dose corticosteroids~* Patients requiring supplemental oxygen therapy~* Prior therapy with gene modified cells~* Previous experimental therapy with SS1 moiety, murine or chimeric antibodies~* History of allergy to murine proteins~* History of allergy or hypersensitivity to study product excipients (human serum albumin, DMSO, and Dextran 40)~* Clinically significant pericardial effusion, CHF, or cardiovascular condition that would preclude assessment of mesothelin induced pericarditis or that may worsen as a result of toxicities expected for this study~* Pregnant or breastfeeding women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CART-meso-19 T cells (Type: EXPERIMENTAL): A single dose of CART-meso-19 T cells (combination therapy with CART-meso and CART19 cells) will be administered intravenously as two separate infusions. The dose is 1-3x107/m2 (Cohort 1) or 1-3x108/m2 (Cohort 2) CART positive cells. The infusion will be scheduled to occur 3 (±1) days after a single dose of 1.5 grams/m2 of cyclophosphamide, which will be administered according to standard procedures in the outpatient setting.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: OPTimizing Irradiation Through Molecular Assesment of Lymph Node After Primary Systemic Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Infiltrating carcinoma of the breast.~* Metastatic lymph nodes (N1) at diagnosis, as determined histologically by Fine Needle Aspiration or Core Needle Biopsy.~* Primary systemic therapy (including antiestrogen or chemotherapy, and targeted therapies).~* Tumour surgery: tumorectomy, quadrantectomy or mastectomy.~* OSNA (ND) or - lymph nodes after primary systemic therapy.~* Age ≥ 18 years old.~* Karnofsky Index ≥ 70 %.~* Signed Informed Consent.~Exclusion Criteria:~* Lymphadenectomy.~* Bilateral breast cancer.~* Males.~* Previous thoracic irradiation therapy.~* Contraindications of radiotherapy (pregnancy, severe collagen diseases).~* Other neoplasms.~* Severe associated comorbidities that, according to the investigator criteria, may interfere with the study evaluations.~* Lymp nodes OSNA -(L), +, ++ after primary systemic therapy.~* Sentinel lymph node biopsy previous to the primary systemic therapy.~* Mammary internal chain affected.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BA3S (Type: ACTIVE_COMPARATOR): Radiotherapy (RT) will be administered, in the breast or thoracic wall, axillary levels I, II and III, and supraclavicular node areas, with optimization of the technique Intentional irradiation of lymph nodes: Patients will receive a total dose of 50 Gy in the whole breast and nodal areas (axillary I, II, III, and supraclavicular) with optimization of the technique, in daily fractions of 2 Gy and 5 fractions/week during 5 weeks.
- BA2 (Type: EXPERIMENTAL): RT will be administered, in the breast or thoracic wall and axillary levels I and II, with optimization of the technique Incidental irradiation of lymph nodes: Patients will receive a total dose of 50 Gy in the whole breast, but not aimed at nodal areas, with optimization of the technique, in daily fractions of 2 Gy and 5 fractions/week during 5 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: High Flow Oxygen Therapy vs Standard Care in Infants With Viral Bronchiolitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of viral bronchiolitis~* Not requiring intubation and ventilation~* Admitted to high care unit~* With moderate/severe respiratory distress (Tal score \>6)~* Saturations \<92% in room air~Exclusion Criteria:~* congenital cardiac disease~* presence of multiorgan failure/multisystemic disease~* previously ventilated~* craniofacial abnormalities~* nasal pathology~* decreased level of consciousness~* Ex-prem \<34 weeks~* Possible impending respiratory failure

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: 2 Years
- Healthy Volunteers: f

Study Arms:
- standard therapy group (Type: NO_INTERVENTION): standard treatment of viral bronchiolitis with low flow oxygen.
- high flow humidified oxygen group (Type: EXPERIMENTAL): treatment of viral bronchiolitis with high flow humidified oxygen therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Interest of New MRI Sequences After Embolization of Brain Arteriovenous Malformations

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient ≥ 18 years old~* with brain Arteriovenous Malformations~* embolization treatment scheduled~Exclusion Criteria:~* patient's refusal to participate in the study~* contraindication to undergo MRI examination~* patient under legal protection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Potential Predictors of Disease Progression in Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Including Genetics, Biomarkers, and Treatment

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Currently receiving eculizumab treatment in the M11-001 aHUS Registry~2. Two normal platelet counts at least 4 weeks apart~3. Two normal lactate dehydrogenase levels at least 4 weeks apart~4. Willing, committed, and able to return for all clinic visits and complete all study-related procedures~5. Participant or participant's parent/legal guardian must have been willing and able to give written informed consent. Participant (if minor) must have been willing to give written informed assent (if applicable as determined by the central Institutional Review Boards/Independent Ethics Committees)~Exclusion Criteria:~1. Any prior eculizumab treatment discontinuation~2. On chronic dialysis (defined as ≥3 months on dialysis)~3. Currently participating in another complement inhibitor trial~4. Life expectancy of \<6 months~5. Participant or participant's parent/legal guardian was unable to give written informed consent. Participant (if minor) was unable to give written informed assent (if applicable as determined by the central Institutional Review Boards/Independent Ethics Committees)

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Eculizumab (Type: None): The targeted population consists of pediatric and adult participants with aHUS who received eculizumab at the discretion of the treating physician.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Campath, Rituximab, and Myfortic With Short-Course Calcineurin Inhibitor Therapy in Renal Transplanation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Recipient of cadaver or non HLA identical living donor transplantation (tx), Re-tx recipient (second tx) allowed, but no organ other than a kidney (ie no prev k/p)~* Females of CBP must have neg preg test at the time of study enrollment (SOC) \& agree to practice birth control for duration of the study, or for 6 weeks after the last dose of Myfortic~Exclusion Criteria:~* Subjects who are pregnant or nursing.~* Current malignancy or a malignancy in the past 5 years, except for excised skin CA (BCC or SC)~* Multi-organ tx, ABO incompatible and + CM~* Subjects with a current PRA \>50% within the past 30 days pre tx~* Subjects with active current infection requiring continued use of antibiotics, or the presence of chronic active hepatitis B (surface antigen +) or +HCV.~* Exclude for subjects who have received an investigational drug within 4 weeks of study entry

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Campath, Rituximab, Myfortic, and 10-20 days of cyclosporine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Rebeccamycin Analogue in Treating Patients With Refractory Stage III or Stage IV Ovarian Epithelial Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS: Histologically or cytologically confirmed stage III or IV ovarian epithelial cancer Platinum resistant disease as defined by disease progression during or within 6 months of receiving prior paclitaxel combined with cisplatin or carboplatin No elevated CA-125 as only evidence of disease recurrence Measurable disease At least 20 mm in diameter by conventional techniques OR At least 10 mm in diameter by spiral CT scan No known brain metastases~PATIENT CHARACTERISTICS: Age: 21 and over Performance status: ECOG 0-2 Life expectancy: Greater than 3 months Hematopoietic: WBC at least 3,000/mm3 Absolute neutrophil count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin normal AST and ALT no greater than 2.5 times upper limit of normal Renal: Creatinine normal OR Creatinine clearance greater than 60 mL/min Other: No history of allergic reactions to compounds of similar chemical or biologic composition to rebeccamycin analogue No other prior cancer within the past 5 years except nonmelanomatous skin cancer No other medical problems that would preclude study Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease Characteristics At least 4 weeks since prior chemotherapy Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: Not specified Other: No other concurrent therapeutic agents for cancer

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues